Lucian Le Cornet

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Journal: Haematologica

Published: May 31, 2025

Author Correction: Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.

Author Correction: Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.

Journal: Nature medicine

Published: April 11, 2025

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: September 22, 2023

Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.

Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.

Journal: Clinical and translational science

Published: July 04, 2023

Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.

Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.

Journal: Nature medicine

Published: March 20, 2023

Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study.

Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study.

Journal: The Lancet. Oncology

Published: July 29, 2022

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Journal: Trials

Published: November 26, 2021

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.

Journal: Trials

Published: April 27, 2021

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

Journal: Nature

Published: October 19, 2020

Dose Estimation for the European Epidemiological Study on Pediatric Computed Tomography (EPI-CT).

Dose Estimation for the European Epidemiological Study on Pediatric Computed Tomography (EPI-CT).

Journal: Radiation research

Published: October 12, 2020

Correction: Validation of Semantic Analyses of Unstructured Medical Data for Research Purposes.

Correction: Validation of Semantic Analyses of Unstructured Medical Data for Research Purposes.

Journal: Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))

Published: January 22, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026